Black Diamond Therapeutics (BDTX) Total Liabilities (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported Total Liabilities for 9 consecutive years, with $28.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 14.32% year-over-year to $28.9 million; the trailing twelve-month figure through Jun 2026 stood at $28.9 million (down 14.32% YoY), and the FY2025 full-year result was $30.8 million, down 21.74% from the prior year.
• Total Liabilities grew to $28.9 million in Q2 2026 per BDTX's latest filing, from $28.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $47.2 million in Q3 2022 and bottomed at $28.6 million in Q1 2026.
• Historically, Total Liabilities has averaged $37.9 million across 5 years, with a median of $38.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 44.35% in 2022, then decreased 21.96% in 2025.
• Over 5 years, Total Liabilities stood at $40.6 million in 2022, then climbed by 3.13% to $41.8 million in 2023, then fell by 5.92% to $39.4 million in 2024, then decreased by 21.74% to $30.8 million in 2025, then dropped by 6.04% to $28.9 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $28.9 million, $28.6 million, and $30.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.